Pitfalls of Drug Development: Lessons Learned from Trials of Denufosol in Cystic Fibrosis
- 1 April 2013
- journal article
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 162 (4), 676-680
- https://doi.org/10.1016/j.jpeds.2012.11.034
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Misrepresentation of Randomized Controlled Trials in Press Releases and News Coverage: A Cohort StudyPLoS Medicine, 2012
- Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic FibrosisJAMA, 2012
- Hypertonic Saline in Treatment of Pulmonary Disease in Cystic FibrosisThe Scientific World Journal, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- TMEM16A Inhibitors Reveal TMEM16A as a Minor Component of Calcium-activated Chloride Channel Conductance in Airway and Intestinal Epithelial CellsPublished by Elsevier BV ,2011
- Cystic fibrosis remodels the regulation of purinergic signaling by NTPDase1 (CD39) and NTPDase3American Journal of Physiology-Lung Cellular and Molecular Physiology, 2010
- Purinergic receptors in airway epitheliaCurrent Opinion in Pharmacology, 2009
- Role of mechanical stress in regulating airway surface hydration and mucus clearance ratesRespiratory Physiology & Neurobiology, 2008
- Advancing Outcome Measures for the New Era of Drug Development in Cystic FibrosisProceedings of the American Thoracic Society, 2007
- A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalitiesThe Journal of Pediatrics, 2001